Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.

about

Apparent Diffusion Coefficient (ADC) predicts therapy response in pancreatic ductal adenocarcinoma.

Item

http://www.wikidata.org/entity/Q47098844

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Apparent Diffusion Coefficient ...... creatic ductal adenocarcinoma.

@en

type

Item

label

Apparent Diffusion Coefficient ...... creatic ductal adenocarcinoma.

@en

prefLabel

Apparent Diffusion Coefficient ...... creatic ductal adenocarcinoma.

@en

P1476

Apparent Diffusion Coefficient ...... creatic ductal adenocarcinoma.

@en

P2093

A Fingerle

http://www.w3.org/2001/XMLSchema#string

A Gupta

http://www.w3.org/2001/XMLSchema#string

A J Beer

http://www.w3.org/2001/XMLSchema#string

C Wörner

http://www.w3.org/2001/XMLSchema#string

I Esposito

http://www.w3.org/2001/XMLSchema#string

I Heid

http://www.w3.org/2001/XMLSchema#string

J T Siveke

http://www.w3.org/2001/XMLSchema#string

M Trajkovic-Arsic

http://www.w3.org/2001/XMLSchema#string

N Teichmann

http://www.w3.org/2001/XMLSchema#string

P Wenzel

http://www.w3.org/2001/XMLSchema#string

P2860

Diffusion-weighted imaging of pancreatic cancer

EGF receptor is required for KRAS-induced pancreatic tumorigenesis

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer

Phase I/II Study of Refametinib (BAY 86-9766) in Combination with Gemcitabine in Advanced Pancreatic cancer.

Differences in the biologic activity of 2 novel MEK inhibitors revealed by 18F-FDG PET: analysis of imaging data from 2 phase I trials.

Diffusion-weighted MRI in the body: applications and challenges in oncology.

Antitumour activity of a potent MEK inhibitor RDEA119/BAY 869766 combined with rapamycin in human orthotopic primary pancreatic cancer xenografts.

Imaging diagnosis of pancreatic cancer: a state-of-the-art review

Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse.

P2888

s41598-017-16826-z

P304

17038

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/S41598-017-16826-Z

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Katja Steiger

P577

2017-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1093128491

http://www.w3.org/2001/XMLSchema#string

P698

29213099

http://www.w3.org/2001/XMLSchema#string

P932

5719052

http://www.w3.org/2001/XMLSchema#string